Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProMIS Neurosciences Inc

0.6310
+0.02103.44%
Volume:20.53K
Turnover:12.44K
Market Cap:20.63M
PE:5.89
High:0.6310
Open:0.6020
Low:0.5860
Close:0.6100
Loading ...

ProMIS Neurosciences Price Target Maintained With a $6.00/Share by Guggenheim

Dow Jones
·
01 Apr

ProMIS Neurosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

ProMIS Neurosciences FY 2024 GAAP EPS $0.11 May Not Be Comparable To $(0.06) Estimate

Benzinga
·
31 Mar

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year

TIPRANKS
·
31 Mar

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

GlobeNewswire
·
31 Mar

ProMIS Neurosciences Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
29 Mar

Danantara Won't Pledge Government Shares, Says Deputy Minister of Finance

Tempo
·
14 Mar

Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
26 Feb

ProMIS Neurosciences Inc - Six-Month Interim Results Expected in 1H 2026, Topline Results in 2H 2026

THOMSON REUTERS
·
25 Feb

ProMIS Neurosciences Doses First Patients in Phase 1B Precise-Ad Trial of Pmn310 for Alzheimer’s Disease

THOMSON REUTERS
·
25 Feb

ProMIS Neurosciences Inc - Precise-Ad Study to Enroll Approximately 100 Subjects Across 22 Sites

THOMSON REUTERS
·
25 Feb

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

GlobeNewswire
·
25 Feb

ProMIS Neurosciences seperates from COO Malenfant, terminates COO position

TIPRANKS
·
20 Feb

World First: TMC and PAMCO Achieve a New Nodule Processing Milestone, Unlocking Critical Energy & Steelmaking Materials at Existing Facilities

GlobeNewswire
·
18 Feb

ProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26

TIPRANKS
·
13 Jan

ProMIS Neurosciences Inc - Study to Enroll 100 Subjects Across 22 U.S. Sites

THOMSON REUTERS
·
10 Jan

ProMIS Neurosciences Inc - Phase 1a Study Shows Favorable Safety Profile for Pmn310

THOMSON REUTERS
·
10 Jan

ProMIS Neurosciences Inc - Patients to Be Dosed Monthly for 12 Months in Phase 1B Trial

THOMSON REUTERS
·
10 Jan

ProMIS Neurosciences Initiates Phase 1B Clinical Trial (Precise-Ad) in Alzheimer’s Disease

THOMSON REUTERS
·
10 Jan

Verizon named a Leader in first-ever 2025 Gartner® Magic Quadrant™ for Private Mobile Network Services

GlobeNewswire
·
10 Jan